Tagged with Swiss Biotech

Switzerland While the Swiss biotech sector is inevitably facing many of the same funding challenges as the global industry and is still struggling to make a meaningful comeback from its 2022 slump, the latest report from the Swiss Biotech Association and EY shows the sector’s resilience with the record revenues of…

Europe The Swiss biotech sector again drew unprecedented levels of investment interest in 2021. Capital investments reached CHF 3.33B (USD 3.53B) in spite of the fact that R&D was focused mainly beyond COVID-19. According to the Swiss Biotech Report presented at the Swiss Biotech Day 2022 in Basel, the sector experienced…

Switzerland Michael Altorfer, CEO of the Swiss Biotech Association, a membership organisation representing the interests of the Swiss biotech industry, discusses the evolution of the biotech sector in Switzerland, how the country’s ecosystem has helped foster success stories like Actelion, and the multilateral work being done to improve intellectual property protection…

Switzerland Switzerland has been long-established as one of the world’s most innovative countries and boasts a thriving ecosystem of startup biotechs. However, a slow and complex funding cycle means that an increasing number of Swiss biotechs are looking towards the US for funding; a trend that risks destabilising and weakening the…

Switzerland The Swiss Biotech Association’s Nic Alexakis describes Switzerland’s thriving biotech scene and extensive support infrastructure, while also highlighting the gaps around early stage funding and the ability of different cantons to collaborate on economic development.  Switzerland of course has quite the reputation as a hub for biotech activity – how…